导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.77% | 3120/4773 |
| 近一周 | -1.74% | 2696/5465 |
| 近一月 | -3.88% | 2882/5421 |
| 近一季 | -2.23% | 1331/5231 |
| 近半年 | -6.56% | 3216/4920 |
| 近一年 | 1.06% | 2575/4394 |
| 近两年 | 40.39% | 1883/2954 |
| 近三年 | 19.28% | 1516/2253 |
| 成立以来 | -34.92% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.01% 1662/4961 |
-1.22% 3339/5312 |
- - |
- - |
| 2025 | 23.05% 1911/4813 |
-1.18% 2602/3635 |
-0.72% 3007/4076 |
25.39% 1401/4524 |
0.03% 2276/4813 |
| 2024 | 4.08% 1893/3463 |
0.66% 945/2808 |
-4.17% 1475/3014 |
13.87% 2087/3129 |
-5.24% 2542/3463 |
| 2023 | -7.47% 921/2656 |
4.03% 1064/2280 |
-4.11% 1056/2385 |
-2.97% 812/2515 |
-4.40% 1009/2655 |
| 2022 | -20.23% 946/2207 |
-14.26% 927/1919 |
6.57% 664/2016 |
-14.09% 1021/2113 |
1.62% 1199/2208 |
| 2021 | 6.14% 524/1822 |
3.35% 183/1255 |
2.55% 1000/1330 |
-3.35% 632/1466 |
3.62% 413/1822 |
| 2020 | 25.75% 613/1250 |
-8.25% 593/1028 |
3.69% 932/1067 |
13.88% 306/1164 |
16.07% 184/1184 |
| 2019 | 18.39% 679/1092 |
21.81% 591/754 |
-5.78% 484/804 |
-4.55% 778/850 |
8.07% 359/918 |
| 2018 | -25.87% 366/834 |
- - |
- - |
- - |
-9.13% 128/691 |
| 2017 | 12.93% 268/714 |
- - |
- - |
- - |
- - |
| 2016 | -14.86% 343/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 长盛中证申万一带一路指数(LOF) VS. 长安沪深300非周期A(740101) |